We are live on
!
Find out more
VAM
Visium Asset Management Portfolio holdings
AUM
$1.43B
1-Year Est. Return
3.58%
This Fund
S&P 500
This Quarter
Est. Return
-12.03%
1 Year Est. Return
-3.58%
3 Year Est. Return
+100.3%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.32B
AUM Growth
+$267M
(+3.8%)
Cap. Flow
+$1.37B
Cap. Flow
% of AUM
18.68%
Top 10 Holdings %
Top 10 Hldgs %
27.6%
Holding
1,433
New
327
Increased
283
Reduced
238
Closed
555
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$306M |
| 2 |
Cigna
CI
|
+$151M |
| 3 |
Pacira BioSciences
PCRX
|
+$143M |
| 4 |
ENDP
Endo International plc
ENDP
|
+$120M |
| 5 |
Tenet Healthcare
THC
|
+$99.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESPR
Esperion Therapeutics
ESPR
|
+$64.7M |
| 2 |
BCR
CR Bard Inc.
BCR
|
+$62.4M |
| 3 |
Perrigo
PRGO
|
+$52.7M |
| 4 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$49.4M |
| 5 |
SKX
Skechers
SKX
|
+$47.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.8% |
| 2 | Financials | 7.09% |
| 3 | Consumer Discretionary | 5.97% |
| 4 | Energy | 5.17% |
| 5 | Industrials | 4.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Goodyear
GT
$2B
| $211K | ﹤0.01% |
7,185
-5,097
| -41% | -$153K |
|
777
iShares Biotechnology ETF
IBB
$9.34B
| $211K | ﹤0.01% |
+2,082
| New | +$250K |
|
778
International Bancshares
IBOC
$4.76B
| $211K | ﹤0.01% |
8,423
-7,399
| -47% | -$194K |
|
779
Navient
NAVI
$789M
| $211K | ﹤0.01% |
18,784
+3,796
| +25% | +$55.5K |
|
780
NNN REIT
NNN
$9.04B
| $211K | ﹤0.01% |
+5,810
| New | +$211K |
|
|
WOOF
781
DELISTED
VCA Inc.
WOOF
| $211K | ﹤0.01% |
4,002
-122
| -3% | -$6.83K |
|
|
NTT
782
DELISTED
Nippon Telegraph & Telephone
NTT
| $210K | ﹤0.01% |
+5,940
| New | +$222K |
|
783
Rayonier
RYN
$6.55B
| $209K | ﹤0.01% |
+10,455
| New | +$226K |
|
784
Oceaneering
OII
$4.86B
| $208K | ﹤0.01% |
+5,285
| New | +$219K |
|
785
Electronic Arts
EA
$53B
| $207K | ﹤0.01% |
+3,060
| New | +$214K |
|
786
Estee Lauder
EL
$30.4B
| $205K | ﹤0.01% |
+2,542
| New | +$213K |
|
787
Greif
GEF
$4.92B
| $205K | ﹤0.01% |
+6,436
| New | +$209K |
|
788
RB Global
RBA
$20.4B
| $204K | ﹤0.01% |
+7,895
| New | +$216K |
|
789
Citigroup
C
$222B
| $202K | ﹤0.01% |
4,071
-57,948
| -93% | -$3.17M |
|
790
Carter's
CRI
$1.42B
| $202K | ﹤0.01% |
+2,232
| New | +$224K |
|
|
ECHO
791
EchoStar
ECHO
$24.4B
| $201K | ﹤0.01% |
5,757
+340
| +6% | +$12.5K |
|
792
Arbutus Biopharma
ABUS
$857M
| $193K | ﹤0.01% |
+31,700
| New | +$281K |
|
|
DF
793
DELISTED
Dean Foods Company
DF
| $193K | ﹤0.01% |
+11,706
| New | +$200K |
|
|
DWA
794
DELISTED
DREAMWORKS ANIMATION SKG INC CL-A
DWA
| $193K | ﹤0.01% |
+11,056
| New | +$239K |
|
|
BGC
795
DELISTED
General Cable Corporation
BGC
| $186K | ﹤0.01% |
+15,612
| New | +$243K |
|
796
Boston Scientific
BSX
$69.5B
| $185K | ﹤0.01% |
+11,300
| New | +$193K |
|
|
CYS
797
DELISTED
CYS Investments Inc.
CYS
| $185K | ﹤0.01% |
25,504
-13,078
| -34% | -$101K |
|
|
FSP
798
Franklin Street Properties
FSP
$47.2M
| $183K | ﹤0.01% |
+16,997
| New | +$190K |
|
799
New York Times
NYT
$12.1B
| $183K | ﹤0.01% |
+15,474
| New | +$195K |
|
|
ACHN
800
DELISTED
Achillion Pharmaceuticals
ACHN
| $180K | ﹤0.01% |
26,000
+2,386
| +10% | +$19.4K |
|
Similar funds
FBNAT
CPS
LH
CPM
VFS
ZA
FVFIGP
WA
Visium Asset Management's Q3 2015 Portfolio in Review
As of Q3 2015, Visium Asset Management held 1,433 positions worth $7.32B, up 3.8% from $7.05B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Visium Asset Management deployed $1.37B of net new capital in Q3 2015, opening 327 new positions and adding to 283 existing holdings. Its largest new stake was Allergan plc: 997,201 shares worth $271M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 49% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Perrigo, an estimated $52.7M trimmed.
- Visium Asset Management's largest Q3 2015 buy was Allergan plc: 997,201 shares worth $271M.
- Visium Asset Management added most to Pacira BioSciences in Q3 2015, an estimated $143M increase.
- Visium Asset Management's biggest Q3 2015 reduction was Perrigo, cutting an estimated $52.7M.
- Visium Asset Management fully exited Esperion Therapeutics in Q3 2015, selling an estimated $64.7M.
- Visium Asset Management's ten largest holdings make up 28% of its $7.32B portfolio in Q3 2015.
- Visium Asset Management opened 327 new positions and closed 555 in Q3 2015.
- Visium Asset Management's portfolio value rose 3.8% quarter-over-quarter to $7.32B.
Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.